Gmt Capital Corp Macrogenics Inc Transaction History

Gmt Capital Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 13, 2020	SELL	$4.28 - $12.11 $1.41 Million - $3.98 Million	-328,278 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$7.95 - $12.27 $8.06 Million - $12.4 Million	-1,013,222 Reduced 75.53%	328,278 $3.57 Million
Q3 2019 Nov 13, 2019	BUY	$12.44 - $17.48 $3.64 Million - $5.11 Million	292,400 Added 27.87%	1,341,500 $17.1 Million
Q2 2019 Aug 14, 2019	BUY	$14.51 - $19.71 $11.5 Million - $15.6 Million	793,900 Added 311.09%	1,049,100 $17.8 Million
Q1 2019 May 13, 2019	BUY	$11.11 - $25.6 $2.84 Million - $6.53 Million	255,200 New	255,200 $4.59 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $219M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Gmt Capital Corp, based on Form 13F filings with the SEC.

Stay updated on Gmt Capital Corp with notifications on news.